Insulin glargine U300 (Toujeo)
Daily concentrated basal insulin analog · insulin class · sc daily · Sanofi
Top dose
titrated
HbA1c reduction
-1.30%
at week 26 · treatment policy
AE discontinuation
2.0%
Status
approved
Pivotal trial
- Trial
- EDITION (insulin-naive)
- Indication
- type 2 diabetes
- Duration
- 26 weeks
- ClinicalTrials.gov
- NCT01499082
- Sponsor
- Sanofi
Notes
Sanofi's concentrated (U300) glargine, the incumbent basal franchise. Included so the insulin competitive set is represented alongside Novo and Lilly. Glycemic efficacy similar to U100 glargine with a flatter profile; hypoglycemia is the differentiator.